Total-body PET scanning to find disease activity and cardiovascular risk in ANCA-associated vasculitis
Official title: PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
Run by University of Edinburgh · NCT07258524 · Data updated 2026-11-12
We will test whether whole-body PET scans with FDG, DOTATATE, and FAPI can detect active inflammation and identify people with active ANCA-associated vasculitis who are at higher long-term cardiovascular risk.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University of Edinburgh Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Edinburgh) |
| Status | Recruiting |
| Started | January 28, 2026 |
| Main results expected | January 2029 |
| Study ends | January 2029 |
| Registry record updated | February 12, 2026 |
| Trial ID | NCT07258524 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with active ANCA-associated vasculitis who can attend the University of Edinburgh for total-body PET scanning within three weeks of starting treatment and who meet safety criteria (not pregnant/breastfeeding, eGFR ≥15 ml/min/1.73 m2, not insulin-dependent diabetic, no tracer hypersensitivity) are ideal candidates.
✕Probably not a fit
People with inactive or well-controlled disease, those who cannot undergo PET scanning (for example due to pregnancy, advanced renal failure, insulin-dependent diabetes, or tracer allergy), or those who cannot be scanned within the early treatment window are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will recruit adults with active ANCA-associated vasculitis and a control group without the disease to undergo total-body PET imaging using FDG, DOTATATE, and FAPI tracers. Baseline scans are planned early in therapy (within three weeks of starting treatment) and imaging findings will be compared with clinical data, blood tests, and standard imaging to characterise disease activity. The study will also examine whether PET-derived measures of inflammation associate with markers of long-term cardiovascular risk. People who are pregnant, breastfeeding, have very low kidney function, insulin-dependent diabetes, or known hypersensitivity to the tracers are excluded.
Why it matters
Potential benefit: If successful, this approach could offer a noninvasive way to detect smouldering vascular inflammation and better identify patients at increased long-term cardiovascular risk so care can be more precisely targeted.
How similar studies have gone: FDG PET has shown promise in other vasculitis types, but using total-body FDG alongside DOTATATE and FAPI in ANCA-associated vasculitis is relatively novel and not yet established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18+ years of age 2. Diagnosis of active AAV (AAV group) Exclusion Criteria: 1. Outwith early treatment window (must receive baseline scan \<3 weeks from starting treatment) 2. Pregnancy or breastfeeding 3. Advanced renal dysfunction (eGFR \<15ml/min/1.73m2) 4. Adverse reaction or hypersensitivity to proposed radiotracers 5. Insulin-dependent diabetes mellitus 6. Patients without mental capacity or willingness to provide informed consent
Where it's running
-
University of Edinburgh
Edinburgh, United Kingdom Recruiting
Study contacts
- Principal investigator: Neeraj Dhaun, MBChB PhD — University of Edinburgh
- Study coordinator: Neeraj Dhaun, MBChB PhD
- Email: bean.dhaun@ed.ac.uk
- Phone: 01312426777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dermal priming to boost flu vaccine response in people on B cell depletion
This study tests whether applying a topical cream with imiquimod on the skin around vaccination can boost the body’s response to the flu shot in people who are receiving B cell–depleting therapy.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
Obinutuzumab beta with low-dose steroids in new-onset ANCA-associated glomerulonephritis
This study tests whether adding Obinutuzumab beta to a rapid-tapering glucocorticoid plan can help people with new-onset ANCA-associated glomerulonephritis see if they achieve remission.
-
MTS109 treatment for refractory autoimmune diseases
This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.
-
Dual-target CAR T therapy (CD19 and BCMA) for relapsed or treatment-resistant autoimmune diseases
This will try a single infusion of off-the-shelf (allogeneic) CAR T-cells that target CD19 and BCMA in adults whose autoimmune disease has relapsed or not responded to other treatments.
-
BDB-001 for adults with ANCA-associated vasculitis
This trial will test whether adding the experimental drug BDB-001 to standard induction therapy (cyclophosphamide then azathioprine, or rituximab) helps adults with active ANCA-associated vasculitis achieve remission.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.